Australia’s Circadian Takes Major Step In Marketing New Diagnostic
This article was originally published in PharmAsia News
Executive Summary
Circadian Technologies, an Australian biotech, has signed the first of what it hopes to be several hospital systems to test and market its diagnostic capable of detecting the source of secondary cancers. CEO Robert Klupacs said the tie with Healthscope was the first of similar plans he hopes to announce over the coming year for Circadian's pipeline of products. He said he expects the cancer diagnostic, considered a breakthrough, to be commercialized within months. (Click here for more